Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
NCT ID: NCT05237297
Last Updated: 2023-06-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
72 participants
INTERVENTIONAL
2022-02-17
2022-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers
NCT04639804
Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
NCT00780325
Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian
NCT05181124
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
NCT04139824
Anti-inflammatory Agents and Cholesterol Metabolism
NCT01279395
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ilaprazole & naproxen
Period 1 : Ilaprazole 10mg/tab, one a day, 5 days
Period 2 : naproxen 500mg/tab, twice a day, 4 days and naproxen 500mg/tab, one a day one at the 5 day
Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + naproxen 500mg/tab, twice a day, 5 days
Ilaprazole
Ilaprazole 10mg
Naproxen
Naproxen 500mg
ilaprazole & aceclofenac
Period 1 : Ilaprazole 10mg/tab, one a day, 5 days
Period 2 : aceclofenac 100mg/tab, twice a day, 4 days and aceclofenac 100mg/tab, one a day one at the 5 day
Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + aceclofenac 100mg/tab, twice a day, 5 days
Ilaprazole
Ilaprazole 10mg
Aceclofenac
Aceclofenac 100mg
ilaprazole & celecoxib
Period 1 : Ilaprazole 10mg/tab, one a day, 5 days
Period 2 : celecoxib 200mg/cap, twice a day, 4 days and celecoxib 200mg/cap, one a day one at the 5 day
Period 3 : Ilaprazole 10mg/tab, one a day, 5 days + celecoxib 200mg/cab, twice a day, 5 days
Ilaprazole
Ilaprazole 10mg
Celecoxib
Celecoxib 200mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ilaprazole
Ilaprazole 10mg
Naproxen
Naproxen 500mg
Aceclofenac
Aceclofenac 100mg
Celecoxib
Celecoxib 200mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men weigh more than 55 kg and women weigh more than 50 kg.
3. Those who have a body mass index of 18.5 kg/m2 or more and less than 27.0 kg/m2.
※ Body mass index (kg/m2) = Weight (kg)/\[Height (m)\]2
4. If participants are a woman, participants must apply to one of the following.
* Menopausal (no natural menstruation for at least 2 years)
* Surgical infertility (autonomous exudation or bilateral ovarian resection, intubation ligation, or other infertility)
5. Men who have sexual relationship with women of child bearing potential must give consent to using contraceptive measures(condoms, spermicide, and menstrual cycle control) for at least 28 days after the final administration of clinical trial and clinical drugs (if the male test subject or female partner is infertile, the above contraception is unnecessary).
6. A person who has heard sufficient explanation of this clinical trial and fully understood it, voluntarily decided to participate, and agreed in writing to comply with precautions.
Exclusion Criteria
2. Active peptic ulcer/bleeding or a person with a medical history.
3. A person who tends to bleed or have a blood clotting disorder.
4. Patients with a history of gastrointestinal bleeding or perforation due to NSAID treatment in the past.
5. Those with a history of gastrointestinal diseases (Crohn's disease, ulcerative colitis, etc.) or surgery (except for simple appendectomy or hernia surgery) that can affect the absorption of drugs.
6. Person with a history of significant drug hypersensitivity reactions to the ingredients and additives of clinical trial drugs. In particular, NSAIDs and aspirin such as Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF), sulfonamide, ilaprazole and naproxen, aceclofenac, celecoxib, diclofenac, etc.
7. A person with a history of asthma, rhinitis, and nasal polyps due to aspirin or other NSAIDs (including COX-2 inhibitors).
8. Those with genetic problems such as galactose intolerance, Lap lactase deficiency, or glucose-galactose malabsorption.
9. A person who was judged to be inappropriate as a test subject in a screening test conducted within 28 days before the first administration date of the clinical trial drug.
* In the case of \> 1.25 times the upper limit of AST and ALT normal range in the blood,
* When the potassium concentration in the blood exceeds 5.5 mEq/L,
* Estimated Global Film Rate (eGFR) \<60 mL/min/1.73 m2 using the Modification of Diet in Regular Disease (MDRD) formula
* Immunology and serology tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test) result are positive factors.
* After resting for more than 5 minutes, systolic blood pressure \>150 mmHg or \<\< in vital signs measured at the seat\> Those who showed values corresponding to 90 mmHg, dilator blood pressure \>100 mmHg, or \<50 mmHg.
10. A person who has a history of drug abuse or has tested positive in a urine drug screening test within one year of screening.
11. If the tester determines that the following drugs, excluding topical drugs without significant systemic absorption, may affect this test or affect the safety of the test subject within the relevant period,
* In the case of taking a prescription drug or herbal medicine within 14 days prior to the first administration date of the clinical trial drug,
* In the case of taking general medicines including health foods and vitamin preparations within 7 days prior to the first administration of clinical trial drugs,
* A person who took drugs such as barbital drugs and other drugs inducing and inhibiting drugs within 30 days prior to the first administration of clinical trial drugs.
12. A person who continuously smoked excessively or consumed caffeine or alcohol (caffeine: \>5 cups/day, alcohol: \>210 g/week, tobacco: \>10 g/day) or who cannot stop smoking, caffeine and alcohol consumption during each hospitalization period.
13. A person who has consumed grapefruit-containing food within 7 days prior to the first administration date of clinical trial drugs or cannot be prohibited from taking it during the clinical trial period.
14. A person who participated in another clinical trial within 180 days prior to the first administration date of the clinical trial drug and received the clinical trial drug (in the case of biological agents, it may be based on an extended period considering a half-life).
15. A person who donated whole blood within 60 days prior to the first administration date of clinical trial drugs or donated component blood within 30 days.
16. A person who received a blood transfusion within 30 days prior to the first administration date of the clinical trial drug.
17. Pregnant or lactating women.
18. A person who determines that the tester is inappropriate to participate in clinical trials due to other reasons.
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Il-Yang Pharm. Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minsoo Park, PhD
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IL49NS01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.